Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension: A Randomized Phase 2 Trial
1. 请及时下载文件确认是否正确, 系统将在 2026-03-27 11:43:54 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
WB White, M Azizi, K Ferdinand, DL Cohen…
JACC, 2026
Elsevier
Background XXB750 is a potent and long-acting human monoclonal antibody agonist of the natriuretic peptide receptor-1 (NPR-1), the receptor for atrial natriuretic peptide and B-type natriuretic peptide. Activation of NPR-1 may lower blood pressure (BP) in patients with resistant hypertension through increases in the second messenger cyclic guanosine monophosphate. Objectives The aim of this study was to determine the effect of NPR-1 agonism on 24-hour BP. Methods This phase 2, multicenter, randomized, double-blind …
